Show simple item record

dc.creatorPopović-Đorđević, Jelena B.
dc.creatorJevtić, Ivana
dc.creatorStanojković, Tatjana
dc.date.accessioned2019-01-30T17:57:55Z
dc.date.available2019-01-30T17:57:55Z
dc.date.issued2018
dc.identifier.issn0929-8673
dc.identifier.urihttp://cer.ihtm.bg.ac.rs/handle/123456789/2315
dc.description.abstractBackground: Diabetes mellitus type 2 (DMT2) is an endocrine disease of global proportions which is currently affecting 1 in 12 adults in the world, with still increasing prevalence. World Health Organization (WHO) declared this worldwide health problem, as an epidemic disease, to be the only non-infectious disease with such categorization. People with DMT2 are at increased risk of various complications and have shorter life expectancy. The main classes of oral antidiabetic drugs accessible today for DMT2 vary in their chemical composition, modes of action, safety profiles and tolerability. Methods: A systematic search of peer-reviewed scientific literature and public databases has been conducted. We included the most recent relevant research papers and data in respect to the focus of the present review. The quality of retrieved papers was assessed using standard tools. Results: The review highlights the chemical structural diversity of the molecules that have the common target-DMT2. So-called traditional antidiabetics as well as the newest and the least explored drugs include polypeptides and amino acid derivatives (insulin, glucagon-like peptide 1, dipeptidyl peptidase-IV inhibitors, amylin), sulfonylurea derivatives, benzylthiazolidine-2,4-diones (peroxisome proliferator activated receptor-gamma agonists/glitazones), condensed guanido core (metformin) and sugar-like molecules (alpha-glucosidase and sodium/glucose co-transporter 2 inhibitors). Conclusion: As diabetes becomes a more common disease, interest in new pharmacological targets is on the rise.en
dc.publisherBentham Science Publ Ltd, Sharjah
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/172032/RS//
dc.rightsrestrictedAccess
dc.sourceCurrent Medicinal Chemistry
dc.subjectDMT2en
dc.subjectperoxisome proliferator activated receptor-gamma agonistsen
dc.subjectmetforminen
dc.subjectalpha-glucosidase inhibitorsen
dc.subjectglucagon-likepeptide 1 analoguesen
dc.subjectdipeptidyl peptidase-IV inhibitorsen
dc.subjectamylin analoguesen
dc.subjectsodiumen
dc.titleAntidiabetics: Structural Diversity of Molecules with a Common Aimen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractЈевтић, Ивана; Станојковиц, Татјана П.; Поповић-Ђорђевић, Јелена Б.;
dc.citation.volume25
dc.citation.issue18
dc.citation.spage2140
dc.citation.epage2165
dc.citation.other25(18): 2140-2165
dc.citation.rankM21
dc.identifier.pmid29210642
dc.identifier.doi10.2174/0929867325666171205145309
dc.identifier.rcubConv_3939
dc.identifier.scopus2-s2.0-85048869485
dc.identifier.wos000433035000006
dc.type.versionpublishedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record